Genentech suit over Amgen's Neupogen alleges patent infringement.
Executive Summary
GENENTECH SUIT OVER AMGEN NEUPOGEN PATENT INFRINGEMENT is an outgrowth of negotiations between the two California biotech giants over the use of recombinant gene technology. The suit, which was filed in San Francisco federal court Oct. 16, claims that Neupogen (filgrastim) uses "vectors, host cells and methods covered by the claims of Genentech's patents."